More Top-Level Pharma Changes In India, Cipla Gets CSO
Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.
You may also be interested in...
OPPI Head On Sustaining Supplies In India During The Pandemic
OPPI director general and ex-MSD India chief outlines how pharma in India is ensuring medicines reach patients amid COVID-19, working closely with various stakeholders. De-risking the supply chain and up-skilling sales forces in view of widespread digital engagement are among the key issues firms are addressing.
CEO Pay In India: A Mixed Bag But Multiples Versus Employee Earnings Huge
Managing directors/CEOs of foreign firms in India drew higher remuneration in 2019-20 versus the previous year and overall earnings of peers at Indian firms continued to be way higher in general. CEO-to-employee pay ratios remains stark, reaching over 550 in one case.
Top-Level Churn At Cipla's India Business
A Cipla veteran and CEO of the firm’s India business and other executives have quit, though the Indian company maintains it has underlying strength and continued business momentum to sustain growth. ANI Pharmaceuticals in the US has snapped up one outgoing executive as president and CEO.